| Vol. 14.22 – 7 June, 2022 |
| |
|
|
| Scientists presented an adaptive biomaterial based on two-dimensional networks of protein nanofibrils at a liquid-liquid interface. [Nature Communications] |
|
|
|
| PUBLICATIONSRanked by the impact factor of the journal |
| |
|
|
| A recently introduced gel aspiration-ejection method was used to rapidly fabricate aligned dense collagen hydrogel scaffolds. [Biomaterials] |
|
|
|
| Researchers identified a new circRNA, circRNA422, from rat bone marrow MSCs cultured on sandblasted, large-grit, acid-etched titanium surfaces. [Molecular Therapy] |
|
|
|
| Based on differential expression analysis of RNA sequencing data, scientists found that lncRNA AC132217.4, a 3’UTR-overlapping lncRNA of insulin growth factor (IGF) 2, was highly induced during the osteogenic differentiation of bone marrow MSCs. [Cellular and Molecular Life Sciences] |
|
|
|
| In vitro preservation of pluronic F127-coated alginate-encapsulated canine adipose MSCs-derived insulin-producing cells (IPCs) was performed to verify ready-to-use IPCs. [Scientific Reports] |
| | The osteogenesis-related cell response to the surface lithium ion-modified sandblasted/acid-etched sample was evaluated using two kinds of murine bone marrow stem cells, bipotent ST2 cells and primary multipotent MSCs. [Journal of Biomaterials Applications] |
|
|
| |
|
|
| Through a comprehensive analysis of gene expression during the differentiation of MSCs into osteoblasts, the authors showed that the forkhead transcription factor Foxf2 was a crucial regulator of this process. [Experimental & Molecular Medicine] |
|
|
|
|
|
| Investigators review the clinical experience with use of MSCs in hematopoietic stem cell transplantation for enhancement of engraftment, prevention, and treatment of graft-versus-host disease and hemorrhagic cystitis. [British Journal of Haematology] |
|
|
|
|
| Lytix Biopharma AS announced data from its ATLAS-IT-04 trial in patients with metastatic STS. The data from this Phase II proof of concept study showed that LTX-315 in combination with adoptive cell therapy was able to stabilize the disease in 3 out of 4 fully treated patients. [Lytix Biopharma AS (Oslo Børs)] |
|
|
|
|
| November 16 – 18, 2022 Melbourne, Victoria, Australia |
|
|
|
|
|
| Stem Cell Network – Ottawa, Ontario, Canada |
|
|
|
| China Medical University – Shenyang, China |
|
|
|
| Utrecht University – Utrecht, Netherlands |
|
|
|
| Baylor College of Medicine – Houston, Texas, United States |
|
|
|
| Novo Nordisk – Fremont, California, United States |
|
|
|
|